Epilepsia and paroxyzmal conditions

Advanced search


Full Text:


Epilepsy is the most frequent neurological sign of tuberous sclerosis complex (TSC) and it’s registered in 83.5% of patients. In majority of cases epilepsy begins during the first year of life (63%) and in 38.8% it’s manifesting as infantile spasms. The presence of epilepsy is closely connected with development of mental retardation in TSC. Early treatment of epilepsy is a key to prevention of mental retardation, and preventive treatment with vigabatrin is now advised by some specialists. Possibly high efficasy of vigabatrin in treatment of seizures associated with TSC is partly due to its m-TOR inhibiting property. M-TOR way is widely discussed now as one of the perspective targets for epilepsy treatment, associated or not associated with TSC.

About the Authors

E. D. Belousova
The Russian National Research Medical University named after N. I. Pirogov of the Ministry of Health of the Russian Federation
Russian Federation

MD, Professor, Honored Doctor of the Russian Federation. Department psychoneurology Epileptology, Research Clinical Institute,

ul. Ostrovityanova, 1, Moscow, 117997

M. Y. Dorofeeva
The Russian National Research Medical University named after N. I. Pirogov of the Ministry of Health of the Russian Federation
Russian Federation

PhD, a leading researcher at the Department psychoneurology and Epileptology, Research Clinical Institute,

ul. Ostrovityanova, 1, Moscow, 117997

T. G. Ohapkina
The Russian National Research Medical University named after N. I. Pirogov of the Ministry of Health of the Russian Federation
Russian Federation

doctor-intern of the Department of Neurology, Neurosurgery and Medical Genetics, Faculty of Pediatrics,

ul. Ostrovityanova, 1, Moscow, 117997


1. Belousova E.D. Dorofeeva M.Yu., Pivovarova A.M., Katysheva O.V. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2015; 115 (5): 46-51.

2. Chu-Shore C. J., Major P., Camposano S. et al. The natural history of epilepsy in tuberous sclerosis complex. Epilepsia. 2010; 51 (7): 1236-41.

3. Chu-Shore C.J., Major P., Montenegro M., Thiele E. Cyst-like tubers are associated with TSC2 and epilepsy in tuberous sclerosis complex. Neurology. 2009; 72 (13): 1165-1169.

4. Curatolo P., Moavero R., de Vries P. J. Neurological and neuropsychiatric aspects of tuberous sclerosis complex. Lancet Neurol. 2015; 14 (7): 733-45.

5. Cusmai R., Moavero R., Bombardieri R. et al. Long- term neurological outcome in children with early-onset epilepsy associated with tuberous sclerosis. Epilepsy Behav. 2011; 22 (4): 735-739.

6. de Vries P. Neurodevelopmental, psychiatric and cognitive aspects of tuberous sclerosis complex. In: Kwiatkowsi D. J., Whittemore V.H., Thiele E.A., editors. Tuberous Sclerosis Complex: Genes, Clinical Features. Weinheim: Wiley-Blackwell. 2010; 229-267.

7. Elliott R. E., Carlson C., Kalhorn S.P. et al. Refractory epilepsy in tuberous sclerosis: vagus nerve stimulation with or without subsequent resective surgery. Epilepsy Behav. 2009; 16 (3): 454-460.

8. Guideline for prescribing vigabatrin in children has been revised. Vigabаtrin Paediatric Advisory Group. BMJ. 2000; 320 (7246): 1404-1405.

9. Jansen F. E., Vincken K. L., Algra A. et al. Cognitive impairment in tuberous sclerosis complex is a multifactorial condition. Neurology. 2008; 70 (12): 916-923.

10. Józẃ iak S., Kotulska K., Domanska-Pakie ́ ła D. et al. Antiepileptic treatment before the onset of seizures reduces epilepsy severity and risk of mental retardation in infants with tuberous sclerosis complex. Eur J Paediatr Neurol. 2011; 15 (5): 424-431.

11. Kröll-Seger J., Kaminska A., Moutard M. L. et al. Severe relapse of epilepsy after vigabatrin withdrawal: for how long should we treat symptomatic infantile spasms? Epilepsia. 2007; 48 (3): 612-613.

12. Macias M., Blazejczyk M., Kazmierska P. et al. Spatiotemporal characterization of mTOR kinase activity following kainic acid induced status epilepticus and analysis of rat brain response to chronic rapamycin treatment. PLoS One. 2013 May 28; 8 (5): e64455.

13. Mackay M. T., Weiss S.K., Adams-Webber T. et al; American Academy of Neurology; Child Neurology Society. Practice parameter: medical treatment of infantile spasms: report of the American Academy of Neurology and the Child Neurology Society. Neurology. 2004; 62 (10): 1668-1681.

14. Nabbout R., Hertzberg C., Curatolo P. et al. TOSCA — Tuberous SClerosis registry to increase disease awareness: first interim data on epilepsy. Poster presented at American Epilepsy Society Annual Meeting in Seattle. USA. 12, 2014.

15. Riikonen R., Rener-Primec Z., Carmant L., Dorofeeva M et al. Does vigabatrin treatment for infantile spasms cause visual field defects? An international multicentre study. Dev Med Child Neurol. 2015 Jan; 57 (1): 60-7.

16. Saxena A., Sampson J.R. Epilepsy in Tuberous Sclerosis: Phenotypes, Mechanisms, and Treatments. Semin Neurol. 2015; 35 (3): 269-76.

17. Vignoli A., La Briola F., Turner K. et al. Epilepsy in TSC: certain etiology does not mean certain prognosis. Epilepsia. 2013; 54 (12): 2134-2142.

18. Wheless J.W., Carmant L., Bebin M. et al. Magnetic resonance imaging abnormalities associated with vigabatrin in patients with epilepsy. Epilepsia. 2009; 50 (2): 195-205.

19. Wong M. Mechanisms of epileptogenesis in tuberous sclerosis complex and related malformations of cortical development with abnormal glioneuronal proliferation. Epilepsia. 2008; 49 (1): 8-21.

20. Zhang B., McDaniel S.S., Rensing N.R., Wong M. Vigabatrin inhibits seizures and mTOR pathway activation in a mouse model of tuberous sclerosis complex. PLoS One. 2013; 8 (2): e57445.

21. Zamponi N., Petrelli C., Passamonti C., Moavero R., Curatolo P. Vagus nerve stimulation for refractory epilepsy in tuberous sclerosis. Pediatr Neurol. 2010; 43 (1): 29-34.

For citation:

Belousova E.D., Dorofeeva M.Y., Ohapkina T.G. TREATMENT OF EPILEPSY IN TUBEROUS SCLEROSIS. Epilepsia and paroxyzmal conditions. 2016;8(2):37-42. (In Russ.)

Views: 147

ISSN 2077-8333 (Print)
ISSN 2311-4088 (Online)